S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
OncLive® On Air
00:00
Introduction
Exploring the FDA approval of Siltocel for relapsed or refractory multiple myeloma patients, comparing CAR-T cell therapy benefits to standard care regimens, and discussing the impact on earlier treatment settings and patient accessibility.
Play episode from 00:00
Transcript
